Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: glutaminyl cyclase inhibitors - Vivoryon Therapeutics

Drug Profile

Research programme: glutaminyl cyclase inhibitors - Vivoryon Therapeutics

Alternative Names: PQ 1565

Latest Information Update: 26 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Probiodrug
  • Developer University of Kiel; Vivoryon Therapeutics
  • Class Antidementias; Antineoplastics; Neuroprotectants; Small molecules
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Cancer

Most Recent Events

  • 08 Jul 2019 MorphoSys signs worldwide license option agreement (development and commercialisation) with Vivoryon Therapeutics for its glutaminyl cyclase inhibitors for Cancer
  • 08 Jul 2019 MorphoSys plans preclinical validation studies in Cancer (Combination therapy)
  • 27 Jun 2019 Vivoryon Therapeutics and University of Kiel agree to co-develop Glutaminyl-peptide cyclotransferase-like (QPCTL) inhibitors for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top